Christina R. Cox
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christina R. Cox has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Margaret V. Powers-Fletcher
College of Medicine, University of Cincinnati, Cincinnati, OH, USA
2 shared publications - Andrew P. Norgan
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
1 shared publication - Clayton A. Benevides
Comisso Nacional de Energia Nuclear, Centro Regional de Cincias Nucleares do Nordeste, Recife, Pernambuco, Brazil
1 shared publication - Cícero Pinheiro Inácio
Department of Mycology, Federal University of Pernambuco, Av. Prof. Moraes Rego, s/n, Cidade Universitária, Recife 50670-901, PE, Brazil
1 shared publication - David S. Askew
Department of Pathology & Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, USA
1 shared publication Eleanor A. Powell
Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
1 shared publication
Latest Publications
- 12 February 2026
- Published by Elsevier in Clinical Microbiology Newsletter
- Vol. 55, 1-3
Microbe snapshot: Chagas disease
- 12 February 2026
- Published by Elsevier in Clinical Microbiology Newsletter
- Vol. 55, 1-3
Microbe snapshot: Chagas disease
- Open Access
- 12 January 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Sensors Journal
- Vol. 26 (4) , 6233-6245
Transforming Blood Infection Diagnostics: AI and Electronic Noses Target Candida
Candidemia is a severe fungal bloodstream infection with high mortality rates, especially in immunocompromised patients. Traditional diagnostic methods, such as blood cultures, suffer from low sensitivity and long turnaround times, delaying targeted antifungal therapy. In this study, we explore the potential of electronic noses (e-noses) combined with artificial intelligence (AI) models to provide a rapid and accurate diagnosis of Candida infections directly from blood culture broth samples. Samples were analyzed using an e-nose, generating datasets that underwent preprocessing steps including outlier removal, cycle equalization, feature transformation, and optional oversampling to address species imbalances. To ensure clinical relevance, we employed a dual-scenario validation strategy, assessing both intrasample sensor stability and intersample biological generalization. We tested both traditional machine learning models and time-series classifiers, selecting models based on prior research and performance in similar tasks. The best-performing models were evaluated based on accuracy, precision, recall, F1-score, specificity, and computational efficiency. Results demonstrated that while the framework achieved >98% consistency in sensor stability tests, the support vector classifier (SVC) emerged as the most robust model for generalization, achieving statistical parity with complex time-series models like InceptionTime, but with significantly higher computational efficiency. This study highlights the feasibility of AI-enhanced e-noses for rapid Candida detection, offering a promising alternative to conventional diagnostics in clinical settings.
- 12 January 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Sensors Journal
- Vol. 26 (4) , 6233-6245
Open AccessTransforming Blood Infection Diagnostics: AI and Electronic Noses Target Candida
Candidemia is a severe fungal bloodstream infection with high mortality rates, especially in immunocompromised patients. Traditional diagnostic methods, such as blood cultures, suffer from low sensitivity and long turnaround times, delaying targeted antifungal therapy. In this study, we explore the potential of electronic noses (e-noses) combined with artificial intelligence (AI) models to provide a rapid and accurate diagnosis of Candida infections directly from blood culture broth samples. Samples were analyzed using an e-nose, generating datasets that underwent preprocessing steps including outlier removal, cycle equalization, feature transformation, and optional oversampling to address species imbalances. To ensure clinical relevance, we employed a dual-scenario validation strategy, assessing both intrasample sensor stability and intersample biological generalization. We tested both traditional machine learning models and time-series classifiers, selecting models based on prior research and performance in similar tasks. The best-performing models were evaluated based on accuracy, precision, recall, F1-score, specificity, and computational efficiency. Results demonstrated that while the framework achieved >98% consistency in sensor stability tests, the support vector classifier (SVC) emerged as the most robust model for generalization, achieving statistical parity with complex time-series models like InceptionTime, but with significantly higher computational efficiency. This study highlights the feasibility of AI-enhanced e-noses for rapid Candida detection, offering a promising alternative to conventional diagnostics in clinical settings.
- 10 April 2024
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 62 (4) , e0161123
Clinical utility of multiplex PCR in the detection of pathogens from sterile body fluids
Rapid identification of pathogens in normally sterile body fluid (NSBF) is essential for appropriate patient management, specifically antimicrobial therapy. Limited sensitivity and increased time to detection of traditional culture prompted us to evaluate additional testing to contribute to the diagnosis of infection. The purpose of this study was to evaluate the GenMark Dx ePlex Blood Culture Identification (BCID) Panels on positive body fluids inoculated into blood culture bottles for the detection of microorganisms. A total of 88 positive body fluids from blood culture bottles were analyzed using a Gram-Positive, Gram-Negative, and/or Fungal pathogen BCID Panel based on the Gram stain result. Each result was compared to routine culture performed from the positive bottle. When using culture as a reference standard, we found the ePlex multiplex panel performed with a positive percent agreement of 96.5% and a negative percent agreement of 99.8%. The use of multiplex PCR may be a useful supplement to routine culture for NSBF in blood culture bottles. IMPORTANCE: The identification of pathogens in normally sterile body fluid (NSBF) is performed using routine culture, the current gold standard. Limitations of this method include sensitivity and increased turnaround times which could potentially delay vital patient care, especially antimicrobial therapy. Adaptations of NSBF in blood culture bottles prompted us to consider the utility of additional methods to bridge the gap in diagnostic challenges for these life-threatening infections. Multiplex molecular panels have been manufactured for use with multiple specimen types including blood, cerebral spinal fluid, stool, and respiratory. Therefore, the purpose of this study was to evaluate the off-label use of ePlex Blood Culture Identification Panels on positive body fluids grown in blood culture bottles for the detection of microorganisms for research purposes.
- 10 April 2024
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 62 (4) , e0161123
Clinical utility of multiplex PCR in the detection of pathogens from sterile body fluids
Rapid identification of pathogens in normally sterile body fluid (NSBF) is essential for appropriate patient management, specifically antimicrobial therapy. Limited sensitivity and increased time to detection of traditional culture prompted us to evaluate additional testing to contribute to the diagnosis of infection. The purpose of this study was to evaluate the GenMark Dx ePlex Blood Culture Identification (BCID) Panels on positive body fluids inoculated into blood culture bottles for the detection of microorganisms. A total of 88 positive body fluids from blood culture bottles were analyzed using a Gram-Positive, Gram-Negative, and/or Fungal pathogen BCID Panel based on the Gram stain result. Each result was compared to routine culture performed from the positive bottle. When using culture as a reference standard, we found the ePlex multiplex panel performed with a positive percent agreement of 96.5% and a negative percent agreement of 99.8%. The use of multiplex PCR may be a useful supplement to routine culture for NSBF in blood culture bottles. IMPORTANCE: The identification of pathogens in normally sterile body fluid (NSBF) is performed using routine culture, the current gold standard. Limitations of this method include sensitivity and increased turnaround times which could potentially delay vital patient care, especially antimicrobial therapy. Adaptations of NSBF in blood culture bottles prompted us to consider the utility of additional methods to bridge the gap in diagnostic challenges for these life-threatening infections. Multiplex molecular panels have been manufactured for use with multiple specimen types including blood, cerebral spinal fluid, stool, and respiratory. Therefore, the purpose of this study was to evaluate the off-label use of ePlex Blood Culture Identification Panels on positive body fluids grown in blood culture bottles for the detection of microorganisms for research purposes.
- Open Access
- 14 December 2023
- Published by American Society for Microbiology in Journal of Microbiology & Biology Education
- Vol. 24 (3)
A simple undergraduate laboratory exercise for teaching the role of sentinel-level clinical microbiology testing in biological threat identification
Undergraduate students in the biomedical sciences are mostly unaware of how clinical microbiology laboratories handle suspected agents of bioterrorism or emerging infectious diseases. The Public Health Security Bioterrorism Preparedness and Response Act of 2002 requires the US Department of Health and Human Services (HHS) to maintain a list of microbes that pose serious biological threats to human health and safety, including Tier 1 agents with the potential for use in bioterrorism. The Laboratory Response Network (LRN), founded by the Centers for Disease Control and Prevention, the Federal Bureau of Investigation, and the Association of Public Health Laboratories, coordinates the response of sentinel, reference, and national laboratories to these biothreats. The sentinel laboratories, which comprise most hospital-based and commercial laboratories, are the first to encounter a suspicious agent. For this reason, the LRN has published a series of testing guidelines to assist the sentinel laboratories in deciding whether a microbial isolate should be considered potentially hazardous and thus sent to a reference or national laboratory for further characterization. Here, we describe a simple laboratory exercise that teaches sentinel-level testing requirements in the context of an applied setting of a potential outbreak of anthrax that would require a sentinel laboratory to recognize a potential threat, attempt to rule it out, and refer to a national laboratory for identification.
- 14 December 2023
- Published by American Society for Microbiology in Journal of Microbiology & Biology Education
- Vol. 24 (3)
Open AccessA simple undergraduate laboratory exercise for teaching the role of sentinel-level clinical microbiology testing in biological threat identification
Undergraduate students in the biomedical sciences are mostly unaware of how clinical microbiology laboratories handle suspected agents of bioterrorism or emerging infectious diseases. The Public Health Security Bioterrorism Preparedness and Response Act of 2002 requires the US Department of Health and Human Services (HHS) to maintain a list of microbes that pose serious biological threats to human health and safety, including Tier 1 agents with the potential for use in bioterrorism. The Laboratory Response Network (LRN), founded by the Centers for Disease Control and Prevention, the Federal Bureau of Investigation, and the Association of Public Health Laboratories, coordinates the response of sentinel, reference, and national laboratories to these biothreats. The sentinel laboratories, which comprise most hospital-based and commercial laboratories, are the first to encounter a suspicious agent. For this reason, the LRN has published a series of testing guidelines to assist the sentinel laboratories in deciding whether a microbial isolate should be considered potentially hazardous and thus sent to a reference or national laboratory for further characterization. Here, we describe a simple laboratory exercise that teaches sentinel-level testing requirements in the context of an applied setting of a potential outbreak of anthrax that would require a sentinel laboratory to recognize a potential threat, attempt to rule it out, and refer to a national laboratory for identification.